7 Biotechs With Catalysts in the Next Month
If there is one area that can generate riches for speculative investors, it would have to be biotech and emerging pharmaceuticals. After all, how many companies can go from nothing to billions in sales so quickly? Savvy investors are also well aware that these companies can turn a large fortune into a small one for those speculative investors who make the wrong moves.
In simpler terms, these updates within the industry have the potential to make or break biopharma companies.
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
NovoCure Ltd. (NASDAQ: NVCR) has multiple presentations in tumor treating fields scheduled for September 15 to 18 at the American Society for Radiation Oncology meeting in Chicago.
Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) will present preclinical data of oncostatin M receptor beta expression in chronic pruritic diseases at the European Society for Dermatological Research annual meeting in France. The meeting is scheduled on for September 18 to 21.
Turning Point Therapeutics Inc. (NASDAQ: TPTX) is releasing updated Phase 1 Trident-1 data and preclinical TPX-0046 data at the European Society for Medical Oncology (ESMO) on September 28.
G1 Therapeutics Inc. (NASDAQ: GTHX) has an investor event scheduled at the ESMO on September 29. At this time, the firm will report preliminary G1T48 Phase 1 data, lerociclib dose escalation data in non-small cell lung cancer and trilaciclib Phase 2 data in small cell lung cancer.
Audentes Therapeutics Inc. (NASDAQ: BOLD) will release an update on Aspiro at the International Annual Congress of the World Muscle Society on October 1 to 5 in Denmark. The Aspiro trial is exploring a treatment for X-linked myotubular myopathy.
ObsEva S.A. (NASDAQ: OBSV) is releasing full safety data from its Implant 2 study at the 75th American Society for Reproductive Medicine in Philadelphia. This data will be presented on October 12 to 16.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) has a Prescription Drug User Fee Act (PDUFA) for Ultomiris scheduled for October 19. Ultomiris is a treatment option for adult patients living with paroxysmal nocturnal hemoglobinuria.